Depression Clinical Trial
— SAMBAOfficial title:
The Biopsychosocial Impact of Mepolizumab in Severe Eosinophilic Asthma on Quantitative and Qualitative Emotional and Affective Outcomes in Patients and Partners
Verified date | October 2023 |
Source | University Hospital Southampton NHS Foundation Trust |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This is a real-life pragmatic non-randomised study to explore the impact of mepolizumab on the emotional and affective outcomes of patients with severe eosinophilic asthma and their partners. It will be conducted in two quantitative stages (Phases 1 and 2) with an additional third qualitative component (Phase 3).
Status | Recruiting |
Enrollment | 120 |
Est. completion date | December 31, 2024 |
Est. primary completion date | December 31, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: Phase 1: - Age 18 or over - Having a diagnosis of severe eosinophilic asthma - Currently on mepolizumab (Nucala®) treatment - At least basic command of English - Giving written informed consent Phase 2 Patient eligibility Inclusion criteria - Age 18 or over - Having a diagnosis of severe eosinophilic asthma - Scheduled to start mepolizumab (Nucala®) treatment - At least basic command of English (for sub-study: conversational level of English that does not require a translator) - Giving written informed consent - Co-habiting with an intimate partner who is willing to participate in the study Exclusion criteria - Participated in Phase 1 - Currently on mepolizumab (Nucala®) treatment - Major psychiatric disorder currently under treatment - History of any major psychiatric disorder in the last 5 years, excluding depressive and anxiety disorders that can be included if treatment or change of treatment (including change in dose of medication) has not started within the last 6 months - Any diagnosed severe comorbid chronic condition that, in the opinion of the patient's asthma physician, might impact on the patient's or partner's affective state (e.g. cancer, diabetes, heart failure, chronic liver disease, chronic kidney disease, autoimmune or neuro-degenerative disease). - Partners only: diagnosis of severe eosinophilic asthma - Death of spouse, main informal carer or first-degree family member within the last 3 months - Current oral corticosteroid maintenance treatment Partner eligibility Inclusion criteria - Age 18 or over - At least basic command of English (for sub-study: conversational level of English that does not require a translator) - Giving written informed consent - Partners: Co-habiting with an intimate partner who has severe eosinophilic asthma and is willing to participate in the study Exclusion criteria - Participated in Phase 1 - Major psychiatric disorder currently under treatment - Participant self-reported history of any major psychiatric disorder in the last 5 years, excluding depressive and anxiety disorders that can be included if treatment or change of treatment (including change in dose of medication) has not started within the last 6 months. - Participant self-reported any diagnosed severe comorbid chronic condition that, in the opinion of the patient's asthma physician, might impact on the patient's or partner's affective state (e.g. cancer, diabetes, heart failure, chronic liver disease, chronic kidney disease, autoimmune or neuro-degenerative disease). - Diagnosis of severe eosinophilic asthma - Death of spouse, main informal carer or first-degree family member within the last 3 months - Current oral corticosteroid maintenance treatment Phase 3: Phase 3 is a qualitative study on a sample of couples from Phase 2 therefore the same exclusion criteria will apply as in Phase 2. |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Department of Respiratory Medicine, Aberdeen Royal Infirmary | Aberdeen | Grampian |
United Kingdom | Glasgow Gartnavel General Hospital | Glasgow | |
United Kingdom | Hull University Teaching Hospitals NHS Trust | Hull | Yorkshire |
United Kingdom | Portsmouth Hospitals NHS Trust | Portsmouth | |
United Kingdom | Judit Varkonyi-Sepp | Southampton | Hampshire |
United Kingdom | Pinderfields Hospital | Wakefield | Yorkshire |
Lead Sponsor | Collaborator |
---|---|
University Hospital Southampton NHS Foundation Trust | Portsmouth Hospitals NHS Trust, University of Derby |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | change in Inflammatory panel and chemokines | Olink inflammatory panel and particular chemokines that are comprehensively listed at https://www.olink.com/content/uploads/2019/04/Olink-Inflammation-Validation-Data-v3.0.pdf) will be used to measure markers of systemic inflammation and assess links between affective states and systemic inflammation. In addition, Serum CCl17 and CCL26 will be measured by ELISA as these biomarkers do not feature in the Olink inflammatory panel. | Phase 2 only: change from baseline to 1 year after start of treatment | |
Other | lived experiences and psychological processes (using Semi-structured interviews) | Interviews to explore participants' quality of life | Phase 2 only: change from baseline to 1 year after start of treatment | |
Primary | Change in emotional composition (using the Geneva Emotions Wheel) | A 20-item self-report questionnaire identifying 20 discrete emotions with positive or negative valence. The intensity of each emotion can be marked on a 6-point Likert-type scale. Lower scores indicate lower intensity of emotions, higher scores indicate higher intensity of emotions. Respondents can add free text. Can be used a a variety of applications. The emotion labels used in the study have been modified with input from representatives of the target study population to ensure complete relevance to the study.. | Phase 1: on enrolment. Phase 2: change to one year after start of treatment | |
Secondary | change in affective state (using the Hospital Anxiety and Depression Scale) | Clinical diagnostic self-report questionnaire to assess psychological distress. Consists of anxiety and depression sub-scales. It consists of seven questions for anxiety and seven questions for depression that are in mixed order in the questionnaire. Each question has four possible answers scored from 0-3. There are separate sub-scale scores for anxiety and depression each with cut-off scores 0-7: normal, 8-10: borderline abnormal and 11-21: abnormal. The HADS is a self-report tool and takes 2-5minutes to complete. | Phase 1: on enrolment. Phase 2: change from baseline to 1 year after start of treatment | |
Secondary | change in self-reported asthma symptom control (using the Asthma Control Questionnaire) | 6-item clinical questionnaire to establish self-assessed asthma control (questions 1-6) and lung function measured by healthcare professional (item 7). 6 of the questions are patients self-report about their asthma during the previous week regarding symptoms and bronchodilator use. Responses are given on a 7-point scale (0=no impairment, 6= maximum impairment). The ACQ score is the mean of all the questions and therefore between 0 (totally controlled) and 6 (severely uncontrolled). In general, patients with a score below 1.0 have adequately controlled asthma and above 1.0 their asthma is not controlled. Patients with a score between 0.75 and 1.25 have borderline of adequate control. The smallest clinically important change is 0.5. | Phase 1: on enrolment. Phase 2: change from baseline to 1 year after start of treatment | |
Secondary | change in functioning and quality of life (using the St Georges Respiratory Questionnaire) | Clinical questionnaire to assess disease impact on quality of life. QThe questionnaire has two parts. Part 1 (Questions 1 to 8) covers the patients' recollection of their symptoms over the preceding period (range 1 month to 1 year). Part 2 (Questions 9 to 16) is related to the patients' current state. The Activity score covers functioning related to patients' daily physical activity. The Impacts score relates to psychosocial functioning. Although this component relates partly to physical symptoms, it also correlates quite strongly with exercise performance, breathlessness and disturbances of mood (anxiety and depression), therefore it is the broadest component of the questionnaire, covering the whole range of disturbances that respiratory patients experience in their lives. Scoring is weighted, gihres scores indicate worse outcomes. | Phase 1: on enrolment Phase 2: change from baseline to 1 year after start of treatment | |
Secondary | change in asthma-related quality of life (using the Severe Asthma Questionnaire) | Questionnaire assessing the impact of severe asthma and the effects of treatment on patient's self-reported health-related quality of life. The questionnaire produces two scores: the SAQ score is the aggregation of 16 different QoL domains and the SAQ-global score is the figure given on a 100-point scale. Higher scroes indicate higher adverese impact on the responder's life.The scale takes between 3 to 6 minutes to complete, but completion time reduces on subsequent occasions. | Phase 1: on enrolment Phase 2: change from baseline to 1 year after start of treatment | |
Secondary | change in illness perception (using the Brief Illness Perception Questionnaire) | Questionnaire assessing the beliefs individuals have about the cause, controllability and impact on them of the illness. Comprises 9 questions. 8 questions use a Likert scale response. Question 9 can be answered by free text about the perceived cause of illness. | Phase 2: change from basline to 1 year after start of treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05777044 -
The Effect of Hatha Yoga on Mental Health
|
N/A | |
Recruiting |
NCT04977232 -
Adjunctive Game Intervention for Anhedonia in MDD Patients
|
N/A | |
Recruiting |
NCT04043052 -
Mobile Technologies and Post-stroke Depression
|
N/A | |
Completed |
NCT04512768 -
Treating Comorbid Insomnia in Transdiagnostic Internet-Delivered Cognitive Behaviour Therapy
|
N/A | |
Recruiting |
NCT03207828 -
Testing Interventions for Patients With Fibromyalgia and Depression
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT06011681 -
The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
|
||
Completed |
NCT04476446 -
An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives
|
Phase 3 | |
Recruiting |
NCT02783430 -
Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease
|
Phase 2/Phase 3 | |
Recruiting |
NCT05563805 -
Exploring Virtual Reality Adventure Training Exergaming
|
N/A | |
Completed |
NCT04598165 -
Mobile WACh NEO: Mobile Solutions for Neonatal Health and Maternal Support
|
N/A | |
Completed |
NCT03457714 -
Guided Internet Delivered Cognitive-Behaviour Therapy for Persons With Spinal Cord Injury: A Feasibility Trial
|
||
Recruiting |
NCT05956912 -
Implementing Group Metacognitive Therapy in Cardiac Rehabilitation Services (PATHWAY-Beacons)
|
||
Completed |
NCT05588622 -
Meru Health Program for Cancer Patients With Depression and Anxiety
|
N/A | |
Recruiting |
NCT05234476 -
Behavioral Activation Plus Savoring for University Students
|
N/A | |
Active, not recruiting |
NCT05006976 -
A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study
|
N/A | |
Enrolling by invitation |
NCT03276585 -
Night in Japan Home Sleep Monitoring Study
|
||
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Recruiting |
NCT05449002 -
Digital Single Session Intervention for Youth Mental Health
|
N/A |